Trial Profile
A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs HIV vaccine Ad26 ENVA-01 (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary) ; HIV gp140 vaccine
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms APPROACH
- Sponsors Janssen Vaccines and Prevention
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 10 May 2022 Planned End Date changed from 1 Jul 2022 to 18 Jul 2022.
- 12 Apr 2022 Planned End Date changed from 18 Jul 2022 to 1 Jul 2022.